Birdshotters who have been receiving Avastin® to deal with their macula oedema will no doubt be interested to read the results of this recent study which compares intravitreal bevacizumab (Avastin®) versus the steroid triamcinolone.  The trial in question concerned people with diabetic macula oedema.The trial suggests that long term at 12 months the results are better for those treated with intravitreal bevacizumab (Avastin®) and part of the reasons given is that cataracts are less likely to develop as a result of the treatment.

BUS suspects that the results might be similar for Birdshotters with macular oedema being treated in this way and perhaps researchers will be checking this out in the future?

http://www.medscape.org/viewarticle/815302